Tumors in a small proportion of pediatric and adult responders relapsed after treatment with CD19 CAR-T cells because of CD19 deletion and CD19 tumor cell growth81,351,352, which results from acquired resistance to CAR-T therapy due to antigen escape90,353,354. Here, CD19 is linked to neoplasm.